Rodriguez v. United States

District Court, S.D. New York·Decided May 19, 2026·No. 7:24-cv-09703·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------x DANNY C. RODRIGUEZ, as father and natural guardian of J.R., an infant,

OPINION & ORDER Plaintiff, ON MOTION TO DISMISS

- against - No. 24-CV-9703 (CS)

United States of America,

Defendant. -------------------------------------------------------------x

Appearances:

Jeffrey D. Hummel Burdo, Rubin & Sachs, Esqs. Melville, New York Counsel for Plaintiff

Mary Ellen Brennan Assistant United States Attorney Southern District of New York New York, New York Counsel for Defendant

Seibel, J.

Before the Court is Defendant’s Motion to Dismiss. (ECF No. 28.) For the following reasons, the motion is GRANTED. I. BACKGROUND For purposes of the motion, I accept as true the facts, but not the conclusions, set forth in Plaintiffs’ Amended Complaint, (ECF No. 14 (“AC”)), as well as the medical records incorporated therein. Facts On December 18, 2021, J.R. was born at Phelps Hospital in Sleepy Hollow, New York. (ECF No. 30-6 (“Ex. F”) at 253.)1 The following day, he was administered and passed an 0F Auditory Brainstem Response (“ABR”) test, which screens for issues with the inner ear and the neurological pathways for hearing. (Id. at 256; ECF No. 30-3 (“Ex. C”) at 24; AC ¶ 37; see ECF No. 33 (“P’s Opp.”) at 1 n.1.) Although his routine screening tests revealed an elevated bilirubin level of 12.80,2 he was discharged from the hospital on December 20, 2021, and his parents were 1F directed to follow up with his pediatrician at Open Door Family Medical Center (“Open Door”), a federally funded facility, the following day. (Ex. F at 251, 256; AC ¶ 8.) During a telephone appointment with Open Door the following afternoon, J.R.’s mother expressed concern about the yellowing of his skin. (ECF No. 30-2 (“Ex. B”) at 4.) Because J.R. continued to be jaundiced after presenting with elevated bilirubin levels at the hospital, the doctor at Open Door recommended that J.R.’s parents bring him back to the hospital that day or early the next morning for another bilirubin check. (Id. at 5.) J.R. underwent laboratory testing at Phelps Hospital later that afternoon, and the laboratory received his blood sample at approximately 4:45 p.m. (Id. at 7.) At approximately 6:00 p.m., Phelps Hospital called Open Door and informed a nurse there that the result of J.R.’s bilirubin level of 29.7 was “critical.” (Id.) This result, however, “was not checked, for unknown reasons,” until the following afternoon, at which point a provider at Open Door called J.R.’s mother and told her to immediately bring J.R. to the hospital. (Ex. C

1 The Court omits leading zeroes on the page numbers of the medical records submitted by Defendant. 2 J.R.’s medical records list his “Transcutaneous Bilirubin” level as 15.3, and his “Neonatal Total Bilirubin” level as 12.80. at 19; see Ex. B at 2.) J.R.’s mother was told that if she could not get transportation to the hospital, she should call 911 to get J.R. to the emergency room. (Ex. B at 2.) J.R.’s mother took him to Northern Westchester Hospital (“NWH”), where doctors reported that he was “jaundiced but otherwise vigorous.” (Ex. C at 30.) J.R. was diagnosed with severe hyperbilirubinemia (at

this point 31.3) and received intensive phototherapy, IV hydration and a double volume exchange transfusion. (Id. at 23, 34.) On December 23, 2021, J.R.’s mother called Open Door with an “urgent” question about the lab results and reported that her son was in the neonatal intensive care unit. (ECF No. 34-1 at 316.) When called back, she expressed concern about the “delay from Lab results to when she was called,” and a doctor at Open Door discussed the delay “at length” with J.R.’s parents. (Id.) Open Door’s records indicate that J.R.’s parents “requested [a] meeting with [the] senior attending,” (id.), but it is unclear whether this meeting took place.3 2F On December 25, 2021, the doctors at NWH administered another ABR test “due to hyperbilirubinemia.” (Ex. C at 24.) Despite having passed his initial ABR test six days earlier, J.R. failed this second ABR test in both ears. (Id. at 24, 27.) He did, however, pass his otoacoustic emissions test.4 (Id. at 27.) NWH recommended that he undergo follow-up testing 3F with audiology in a week. (Id.) J.R. was discharged from the hospital that same day, as his bilirubin levels had normalized. (Id. at 18-19.) J.R. had not shown any signs of encephalopathy, and his doctor said that encephalopathy was unlikely given that J.R. had not exhibited any symptoms thus far. (Id. at 24.) Nonetheless, the doctor advised that J.R. continue to be

3 Although the records do not indicate how J.R.’s parents learned of the delay in receiving the results, they show that less than an hour before J.R.’s mother called Open Door, a doctor from NWH called Open Door to inquire about the “delay of care from date lab was done.” (ECF No. 34-1 at 317.) 4 This test measures the function of the outer hair cells in the ear, but does not measure a response from the auditory nerve. (ECF No. 32 (“D’s Mem.”) at 4 n.2.) monitored and recommended a follow-up with pediatric neurology. (Id.) J.R. was also referred to a new pediatrician, (id.), and after canceling J.R.’s scheduled follow-up appointment with Open Door, J.R.’s mother informed Open Door that she had found a different facility to care for him, (ECF No. 34-1 at 314).

On December 30, 2021, J.R. underwent a neurological evaluation. (ECF No. 30-5 (“Ex. E”) at 238; AC ¶ 38.) The results of this evaluation were normal “with the exception of lack of elicited response/lateralization to the bell,” and the neurologist noted that a formal audiological evaluation was necessary to assess J.R.’s hearing. (Ex. E at 240; AC ¶ 38.) The neurologist recommended a reevaluation of J.R.’s neurological status in three months, and her notes indicate that she discussed with J.R.’s parents “possible acute clinical manifestations of hyperbilirubin encephalopathy, currently rare incidence of chronic encephalopathy, BIND [bilirubin-induced neurologic dysfunction] and ANSD [auditory neuropathy spectrum disorder].” (Ex. E at 240.) On January 21, 2022, J.R. returned to Phelps Hospital for a follow-up hearing screening. (ECF No. 30-4 (“Ex. D”) at 163.) He again failed the ABR testing in both ears. (Id.; AC ¶ 39.)

Although the AC alleges that “[t]here was no discussion as to the cause of these findings at this time,” (AC ¶ 39), the “history” section of the results noted that J.R. had passed the hearing screening administered immediately after his birth, but that his mother reported that he had failed the repeat screening after he was hospitalized with jaundice at NWH, (Ex. D at 163). Additional testing was recommended, and J.R.’s parents scheduled a follow-up appointment for February 2022. (Id.) On February 11, 2022, J.R. underwent a diagnostic ABR evaluation. (Ex. E at 182; AC ¶ 40.) The results demonstrated “[t]he presence of a large cochlear microphonic and absent ABR response, along with the presence of otoacoustic emissions,” which “suggest[ed] auditory neuropathy/dys-synchrony,” a condition affecting “the neural processing of auditory stimuli.” (Ex. E at 183; see AC ¶ 40.) The audiologists’ report explained that “[p]atients with this disorder may or may not respond to sounds appropriately and have difficulty understanding speech and language,” and thus the “results of objective testing may or may not be a true indicator of a

patient’s hearing.” (Ex. E at 183; see AC ¶ 40.) J.R. was referred to an ear, nose and throat specialist, and his parents were advised to repeat the ABR testing when he was three months old and to take him for behavioral audiological testing at six or seven months to confirm the results. (Ex.

Free access — add to your briefcase to read the full text and ask questions with AI

Rodriguez v. United States, (S.D.N.Y. 2026).

Rodriguez v. United States (Rodriguez v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

§ 2675
28 U.S.C. § 2675